Consortium for Immunotherapeutics against Emerging Viral Threats

针对新兴病毒威胁的免疫治疗联盟

基本信息

项目摘要

SUMMARY: OVERALL This proposal, Consortium for Immunotherapeutics Against Emerging Viral Diseases, addresses a critical gap in the biodefense portfolio by building an academic-industry partnership to advance effective, fully human, antibody-based immunotherapeutics against three major families of emerging/re-emerging viruses: Lassa virus, Ebola and other Filoviruses, and mosquito-transmitted Alphaviruses that threaten millions worldwide. This program follows directly from our significant body of preliminary data (the largest available for these families of viruses), therapeutics in hand, multidisciplinary expertise, and demonstrated collaborative success. Included in the proposed CETR portfolio are: (1) the only available immunotherapeutics against endemic Lassa virus, with reversal of late-stage disease and complete survival in infected non-human primates, (2) novel Ebola and pan- ebolavirus therapeutics that also completely protect non-human primates from disease, and that were built by the paradigm-shifting and comprehensive analysis of a global consortium, and (3) much needed, first-in-class therapeutics against the re-emerging alphaviruses that have tremendous epidemic potential in the United States and around the globe. These multidisciplinary studies, founded upon pioneering structural biology of the antigen targets, include innovations such as agnostic, high-throughput Fc profiling and optimization, coupled with Fv evolution to enhance potency and developability, as well as a sophisticated statistical and computational analysis core to evaluate thresholds and correlates of protection across the major families of pathogens. Together, we aim to understand what findings represent general rules and what data are specific to each virus family. We also aim to provide streamlined systems for antibody choice and optimization that do not yet exist, and to build a broadly applicable platform for mAb discovery and delivery against any novel pathogen as they emerge. The recent resurgence of Lassa, the epidemic nature of Ebola virus and other re-emerging filoviruses, as well as the major population at risk by global movement of mosquito-borne alphaviruses together demonstrate the tremendous global need for immunotherapeutics developed and advanced by this program.
总结:总体

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Erica Ollmann Saphire其他文献

Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae
  • DOI:
    10.1007/s00705-012-1454-0
  • 发表时间:
    2012-09-23
  • 期刊:
  • 影响因子:
    2.500
  • 作者:
    Jens H. Kuhn;Yiming Bao;Sina Bavari;Stephan Becker;Steven Bradfute;J. Rodney Brister;Alexander A. Bukreyev;Kartik Chandran;Robert A. Davey;Olga Dolnik;John M. Dye;Sven Enterlein;Lisa E. Hensley;Anna N. Honko;Peter B. Jahrling;Karl M. Johnson;Gary Kobinger;Eric M. Leroy;Mark S. Lever;Elke Mühlberger;Sergey V. Netesov;Gene G. Olinger;Gustavo Palacios;Jean L. Patterson;Janusz T. Paweska;Louise Pitt;Sheli R. Radoshitzky;Erica Ollmann Saphire;Sophie J. Smither;Robert Swanepoel;Jonathan S. Towner;Guido van der Groen;Viktor E. Volchkov;Victoria Wahl-Jensen;Travis K. Warren;Manfred Weidmann;Stuart T. Nichol
  • 通讯作者:
    Stuart T. Nichol
The C-terminus of Sudan ebolavirus VP40 contains a functionally important CXsubn/subC motif, a target for redox modifications
苏丹埃博拉病毒 VP40 的 C 末端包含一个功能重要的 CXC 基序,这是氧化还原修饰的一个靶点。
  • DOI:
    10.1016/j.str.2023.06.004
  • 发表时间:
    2023-09-07
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Anke-Dorothee Werner;Martin Schauflinger;Michael J. Norris;Michael Klüver;Anna Trodler;Astrid Herwig;Christina Brandstädter;Melissa Dillenberger;Gerhard Klebe;Andreas Heine;Erica Ollmann Saphire;Katja Becker;Stephan Becker
  • 通讯作者:
    Stephan Becker
Infusion of neutralization into Lassa vaccine design
将中和作用注入拉沙疫苗设计中
  • DOI:
    10.1016/j.it.2025.05.006
  • 发表时间:
    2025-07-01
  • 期刊:
  • 影响因子:
    13.900
  • 作者:
    Haoyang Li;Kathryn M. Hastie;Erica Ollmann Saphire
  • 通讯作者:
    Erica Ollmann Saphire
A global collaboration for systematic analysis of broad-ranging antibodies against the SARS-CoV-2 spike protein
针对 SARS-CoV-2 刺突蛋白的广泛抗体的系统分析的全球合作
  • DOI:
    10.1016/j.celrep.2025.115499
  • 发表时间:
    2025-04-22
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Sharon L. Schendel;Xiaoying Yu;Peter J. Halfmann;Jarjapu Mahita;Brendan Ha;Kathryn M. Hastie;Haoyang Li;Daniel Bedinger;Camille Troup;Kan Li;Natalia Kuzmina;Jordi B. Torrelles;Jennifer E. Munt;Melissa Mattocks;Mary Osei-Twum;Heather M. Callaway;The CoVIC-DB Team;Stephen Reece;Anne Palser;Paul Kellam;S. Moses Dennison;Erica Ollmann Saphire
  • 通讯作者:
    Erica Ollmann Saphire
Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop.
人类免疫缺陷病毒 1 型 gp120 V3 环的重复构象。
  • DOI:
    10.1016/s0042-6822(03)00525-7
  • 发表时间:
    2003
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    R. Stanfield;J. Ghiara;Erica Ollmann Saphire;A. Profy;I. Wilson
  • 通讯作者:
    I. Wilson

Erica Ollmann Saphire的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Erica Ollmann Saphire', 18)}}的其他基金

Structure of the SARS-CoV-2 Nucleocapsid: building block to viral capsid
SARS-CoV-2 核衣壳的结构:病毒衣壳的构建模块
  • 批准号:
    10728253
  • 财政年份:
    2023
  • 资助金额:
    $ 714.34万
  • 项目类别:
Integrative Immunogen Design and Testing
综合免疫原设计和测试
  • 批准号:
    10842890
  • 财政年份:
    2021
  • 资助金额:
    $ 714.34万
  • 项目类别:
Consortium for Immunotherapeutics against Emerging Viral Threats
针对新兴病毒威胁的免疫治疗联盟
  • 批准号:
    10447562
  • 财政年份:
    2021
  • 资助金额:
    $ 714.34万
  • 项目类别:
Integrative Immunogen Design and Testing
综合免疫原设计和测试
  • 批准号:
    10328121
  • 财政年份:
    2021
  • 资助金额:
    $ 714.34万
  • 项目类别:
Consortium for Immunotherapeutics against Emerging Viral Threats
针对新兴病毒威胁的免疫治疗联盟
  • 批准号:
    10199909
  • 财政年份:
    2020
  • 资助金额:
    $ 714.34万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10158452
  • 财政年份:
    2019
  • 资助金额:
    $ 714.34万
  • 项目类别:
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses
针对丝状病毒的特异性且广泛活性的单克隆抗体疗法
  • 批准号:
    10402338
  • 财政年份:
    2019
  • 资助金额:
    $ 714.34万
  • 项目类别:
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses
针对丝状病毒的特异性且广泛活性的单克隆抗体疗法
  • 批准号:
    10158448
  • 财政年份:
    2019
  • 资助金额:
    $ 714.34万
  • 项目类别:
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The Filoviruses
针对丝状病毒的特异性且广泛活性的单克隆抗体疗法
  • 批准号:
    10617736
  • 财政年份:
    2019
  • 资助金额:
    $ 714.34万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10617743
  • 财政年份:
    2019
  • 资助金额:
    $ 714.34万
  • 项目类别:

相似海外基金

Intracellular functions and mechanisms of alphavirus ion channel 6K
甲病毒离子通道6K的细胞内功能和机制
  • 批准号:
    10727819
  • 财政年份:
    2023
  • 资助金额:
    $ 714.34万
  • 项目类别:
Elucidating the mechanisms of alphavirus subgenomic RNA translation
阐明甲病毒亚基因组 RNA 翻译机制
  • 批准号:
    10678281
  • 财政年份:
    2023
  • 资助金额:
    $ 714.34万
  • 项目类别:
Development of a Cross-Protective New World Encephalitic Alphavirus Subunit Vaccine
交叉保护性新世界脑炎甲病毒亚单位疫苗的研制
  • 批准号:
    10696914
  • 财政年份:
    2023
  • 资助金额:
    $ 714.34万
  • 项目类别:
Defining the Molecular Determinants of Encephalitic Alphavirus Viremia
定义脑炎甲病毒血症的分子决定因素
  • 批准号:
    10599124
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Defining the Molecular Determinants of Encephalitic Alphavirus Viremia
定义脑炎甲病毒血症的分子决定因素
  • 批准号:
    10384551
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Center of Excellence for Encephalitic Alphavirus Therapeutics
脑炎甲病毒治疗卓越中心
  • 批准号:
    10631703
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1
甲病毒感染性和适应机制 - 重新提交 - 1
  • 批准号:
    10556424
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Structural Mechanisms of Alphavirus Membrane Fusion
甲病毒膜融合的结构机制
  • 批准号:
    10444088
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Structural Mechanisms of Alphavirus Membrane Fusion
甲病毒膜融合的结构机制
  • 批准号:
    10612929
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
Mechanisms of alphavirus infectivity and adaptation - Resubmission - 1
甲病毒感染性和适应机制 - 重新提交 - 1
  • 批准号:
    10444392
  • 财政年份:
    2022
  • 资助金额:
    $ 714.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了